Search results for "COLON"

showing 10 items of 2038 documents

Occurrence of invading bacteria in radicular dentin of periodontally diseased teeth: Microbiological findings

1997

Bacterial invasion in roots of periodontally diseased teeth, which has been recently documented using cultural and microscopic techniques, may be important in the pathogenesis of periodontal disease. The purpose of this investigation was to determine the occurrence and the species of invading bacteria in radicular dentin of periodontally diseased teeth. Samples were taken from the middle layer of radicular dentin of 26 periodontally diseased teeth. 14 healthy teeth were used as controls. Dentin samples were cultured anaerobically. The chosen methodology allowed the determination of the numbers of bacteria present in both deeper and outer part of dentinal tubules, and the bacterial concentra…

AdultMaleGingival and periodontal pocketColony Count MicrobialDentistryInvading bacteria Periodontal disease Periodontal pathogens Radicular dentin RecurrenceStreptococcus intermediusMicrobiologyBacteria Anaerobicstomatognathic systemRecurrenceDentinmedicineHumansPeriodontal PocketTooth RootPorphyromonas gingivalisPeriodontal Diseasesbiologybusiness.industryPrevotella intermediaBacteria PresentMiddle Agedbiology.organism_classificationstomatognathic diseasesmedicine.anatomical_structureDentinPeriodonticsFemaleFusobacterium nucleatumBacteroidesbusiness
researchProduct

Weekly Dose-Dense Cisplatin-Epirubicin-Paclitaxel Administration with Granulocyte Colony-Stimulating Factor Support Does Not Substantially Improve Pr…

2004

Purpose: The present study was aimed at defining the antitumor activity of the cisplatin-epirubicin-paclitaxel (PET) weekly administration with granulocyte colony-stimulating factor (G-CSF) support in chemonaive small-cell lung cancer patients with extensive disease (ED-SCLC). Methods: Chemonaive ED-SCLC patients received cisplatin 30 mg/sqm, epirubicin 50 mg/sqm and paclitaxel 120 mg/sqm, weekly, with G-CSF (5 μg/kg from day 3 to 5) support, for a maximum of 12 weeks. Results: Thirty-nine patients were treated, for a total of 354 cycles delivered. Eight complete (21%), and 22 partial responses (56%) were recorded, giving a 77% (95% Cl = 61-89%) objective response rate (ORR). After 14 (rang…

AdultMaleLung NeoplasmsPaclitaxelMiddle AgedPrognosisSmall-cell lung cancer Weekly chemotherapy Paclitaxel Epirubicin CisplatinSurvival AnalysisDrug Administration ScheduleTreatment OutcomeAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactorHumansFemaleCarcinoma Small CellCisplatinInfusions IntravenousAgedEpirubicin
researchProduct

Identification of Candida dubliniensis among oral yeast isolates from an italian population of human immunodeficiency virus-infected (HIV +) subjects

2002

Candida dubliniensis, an emerging oral pathogen, phenotypically resembles Candida albicans so closely that it is easily misidentified as such. The aim of the present study was to evaluate the usefulness of two phenotypic methods, growth at 45 degrees C and 2,3,5-triphenyltetrazolium chloride (TTC) reduction, for confirming presumptive identification of C. dubliniensis and C. albicans by colony color on CHROMagar Candida (CAC) medium. A combination of these methods was used to establish the prevalence of oral C. dubliniensis in an Italian population of 45 human immunodeficiency virus (HIV)-infected subjects. Twenty-two samples (48.9%) were positive for yeasts on CAC medium producing a total …

AdultMaleMicrobiology (medical)IdentificationSettore MED/07 - Microbiologia E Microbiologia ClinicaAntifungal AgentsImmunologyColony Count MicrobialTetrazolium SaltsHIV InfectionsPolymerase Chain ReactionMicrobiologyCandidiasis OralDrug Resistance FungalSettore MED/28 - Malattie OdontostomatologicheCandida albicansHumansColoring AgentsDNA FungalFluconazoleCandidaMouthTemperatureHIVMiddle AgedCulture MediaOral cavityAgarPhenotypeChromogenic CompoundsItalyCandida dubliniensiDentistry (all)Female
researchProduct

Follow-up after transanal endoscopic microsurgery or transanal excision of large benign rectal polyps

1998

Methods: Between January 1986 and December 1995, 238 patients with benign rectal polyps under-went either transanal endoscopic microsurgery (n = 226) or transanal excision (n = 12) at the Clinic of General and Abdominal Surgery, Johannes Gutenberg-University, Mainz. Results: Mean polyp size was 4.2 cm; 89.1% of polyps measured more than 2 cm in diameter. In 89.1% of cases, histological analysis revealed polyps containing tubulovillous or villous adenomas. Synchronous colonic polyps were detected in 12.5% of patients. Follow-up data are available on 222 patients (94%). At follow-up examination, 169 of the 193 surviving patients (87.6%) were recurrence free. Seven of 193 patients (3.6%) had d…

AdultMaleMicrosurgerymedicine.medical_specialtymedicine.medical_treatmentAnal CanalColonic PolypsAdenoma VillousHumansMedicineRectal PolypAgedAged 80 and overTransanal ExcisionRectal Neoplasmsbusiness.industryIncidence (epidemiology)EndoscopyColonoscopyMiddle AgedMicrosurgeryPrognosisdigestive system diseasesPolypectomySurgeryCardiac surgeryTreatment OutcomeCardiothoracic surgeryFemaleSurgerybusinessFollow-Up StudiesAbdominal surgeryLangenbeck's Archives of Surgery
researchProduct

Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma

2013

Background: Neutropenia and its complications represent one of the principal dose-limiting toxicity issues in chemotherapeutic regimens for soft tissue sarcoma. Prophylactic granulocyte colony-stimulating factor (G-CSF) reduces the risk of febrile neutropenia (FN). The correct timing of G-CSF administration should be considered in order to optimize the prophylactic treatment. Patients and Methods: Patients (≥18 years old) affected by soft tissue sarcoma and treated with epirubicin and ifosfamide, underwent prophylactic treatment with G-CSF (lenograstim at 263 μg) from day 5 to day 9. The proportion of patients experiencing FN and G4 neutropenia was considered. Results: A total of 36 patient…

AdultMaleNeutropeniaSettore MED/06 - Oncologia MedicaAntineoplastic AgentsSarcomaSoft Tissue Neoplasmslenograstrim sarcoma neutropeniaMiddle AgedLenograstim Febrile Neutropenia Soft tissue sarcomaLenograstimRecombinant ProteinsYoung AdultAdjuvants ImmunologicGranulocyte Colony-Stimulating FactorHumansFemaleIfosfamideAgedEpirubicin
researchProduct

Irinotecan (CPT-11) and Mitomycin-C (MMC) as Second-Line Therapy in Advanced Gastric Cancer

2005

Objective The aim of this study was to evaluate the activity and toxicity of a combination regimen of CPT-11 and mitomycin-c as second-line chemotherapy for pretreated patients with advanced, metastatic, or both, gastric adenocarcinoma. Materials and methods Patients with pretreated metastatic disease or early relapsed after adjuvant chemotherapy were enrolled. Entry criteria included histologic/cytologic diagnosis of gastric adenocarcinoma, age 18 to 75 years, performance status > or =70 (Karnofsky scale), bi-dimensionally measurable disease. Patients received CPT-11 and mitomycin-c at the dosage of 150 mg/m2 on days 1 and 15, and 8 mg/m2 on day 1, respectively, every 4 weeks. The disease …

AdultMaleOncologyCancer Researchmedicine.medical_specialtyLung NeoplasmsNeutropeniaMitomycinmedicine.medical_treatmentSalvage therapyPhases of clinical researchAdenocarcinomaNeutropeniaIrinotecanGastroenterologyDisease-Free SurvivalStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactormedicineHumansLife TablesPeritoneal NeoplasmsAgedSalvage TherapyChemotherapyLeukopeniaPerformance statusbusiness.industryLiver NeoplasmsDrug SynergismMiddle Agedmedicine.diseaseSurvival Analysistherapy gastric cancerIrinotecanRegimenTreatment OutcomeItalyOncologyLymphatic MetastasisCamptothecinFemalemedicine.symptombusinessmedicine.drugAmerican Journal of Clinical Oncology
researchProduct

Effect of priming ith granulocyte-colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia

2003

BACKGROUND: Sensitization of leukemic cells with hematopoietic growth factors may enhance the cytotoxicity of chemotherapy in acute myeloid leukemia (AML). METHODS: In a multicenter randomized trial, we assigned patients (age range, 18 to 60 years) with newly diagnosed AML to receive cytarabine plus idarubicin (cycle 1) and cytarabine plus amsacrin (cycle 2) with granulocyte colony-stimulating factor (G-CSF) (321 patients) or without G-CSF (319). G-CSF was given concurrently with chemotherapy only. Idarubicin and amsacrin were given at the end of a cycle to allow the cell-cycle-dependent cytotoxicity of cytarabine in the context of G-CSF to have a greater effect. The effect of G-CSF on dise…

AdultMaleOncologymedicine.medical_specialtyAcute myeloblastic leukemiamedicine.medical_treatmentDisease-Free SurvivalRecurrenceInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactorHumansMedicineIdarubicinSurvival analysisChemotherapybusiness.industryRemission InductionCytarabineInduction chemotherapyGeneral MedicineLeukemia Myelocytic AcuteMiddle Agedmedicine.diseaseSurvival AnalysisHematopoietic Stem Cell MobilizationGranulocyte colony-stimulating factorSurgeryLeukemia Myeloid AcuteLeukemiaCytarabineFemaleIdarubicinbusinessmedicine.drugNew England Journal of Medicine
researchProduct

Patterns of adjuvant chemotherapy for stage II and III colon cancer in France and Italy

2013

European guidelines recommend adjuvant chemotherapy for stage III colon cancer but not for stage II.To determine the extent to which adjuvant chemotherapy was used in Italy and France.A common retrospective database of 2186 colon cancers diagnosed between 2003 and 2005 was analysed according to age, stage and presenting features.38.9% of patients with stage II and 64.6% with stage III received chemotherapy in Italy, 21.7% and 65.1% in France. For stage II, the association between country and chemotherapy was only significant in patients diagnosed out of emergency (ORItaly/France: 3.05 [2.12-4.37], p0.001) whereas patients diagnosed in emergency were as likely to receive chemotherapy in both…

AdultMaleOncologymedicine.medical_specialtyAdolescentAdjuvant chemotherapyColorectal cancermedicine.medical_treatmentStage iiLower riskDisease-Free SurvivalInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansIn patientStage (cooking)ChildAgedNeoplasm StagingRetrospective StudiesAged 80 and overChemotherapyHepatologybusiness.industryInfant NewbornGastroenterologyInfantMiddle Agedmedicine.diseaseCancer registryItalyChemotherapy AdjuvantChild PreschoolColonic NeoplasmsPractice Guidelines as TopicFemaleFranceGuideline AdherencebusinessDigestive and Liver Disease
researchProduct

Model-based approach to describe G-CSF effects in carboplatin-treated cancer patients.

2013

Granulocyte colony-stimulating factor (G-CSF) is often used in cancer patients receiving cytotoxic drugs to prevent or reduce high grade neutropenia. We propose a pharmacokinetic/pharmacodynamic model to describe myelotoxicity in both G-CSF treated and non-treated patients that shall increase our understanding of G-CSF effects. The model was built from absolute neutrophil counts (ANC) obtained in 375 carboplatin-treated patients, 47 of whom received G-CSF. It includes some prior information on G-CSF taken from the literature. Simulations were performed to understand differences in G-CSF effects and explore the impact of G-CSF formulation. Our model well described the data in all patients. M…

AdultMaleOncologymedicine.medical_specialtyNeutrophilsmedicine.medical_treatment[SDV]Life Sciences [q-bio]Pharmaceutical ScienceAntineoplastic AgentsNeutropeniaModels Biological030226 pharmacology & pharmacyCarboplatinLeukocyte CountYoung Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePharmacokineticsNeoplasmsInternal medicineGranulocyte Colony-Stimulating FactormedicineHumansComputer SimulationPharmacology (medical)Young adultIntensive care medicinePrior informationAgedAged 80 and overPharmacologyChemotherapy[ SDV ] Life Sciences [q-bio]business.industryOrganic ChemistryCancerMiddle Agedmedicine.diseaseCarboplatin3. Good healthchemistry030220 oncology & carcinogenesisPharmacodynamicsMolecular MedicineFemalebusinessBiotechnology
researchProduct

[Effectiveness of contemporary injection of botulinum toxin and topical application of glyceryl trinitrate against postoperative pain after Milligan-…

2007

PURPOSE: After haemorrhoidectomy the maximum resting pressure (MRP) of the anal canal is significantly increased. This increase play an important role in the making of postoperative pain. Recently, both the topical application of glyceryl trinitrate (GT) and the intrasphincter injection of botulinum toxin (Tox), resulted effective, in reducing temporary the MRP although with different mechanism of action. In this study the effectiveness and safe of contemporary injection of Tox and topical application of 300 mg/die of GT after Milligan-Morgan haemorrhoidectomy, were evaluated. MATERIALS AND METHODS: Ten patients, undergoing Milligan-Morgan haemorrhoidectomy for 3rd and 4th degree haemorrhoi…

AdultMalePain PostoperativeAdministration TopicalVasodilator AgentsColonoscopynHemorrhoidsInjectionsNitroglycerinNeuromuscular AgentsHumansDrug Therapy CombinationFemaleBotulinum Toxins Type AAnnali italiani di chirurgia
researchProduct